Cargando…
Clinical value of 3'-deoxy-3'-[(18)F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer
Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited acc...
Autores principales: | Alwadani, Bandar, Dall’Angelo, Sergio, Fleming, Ian N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253862/ https://www.ncbi.nlm.nih.gov/pubmed/34213667 http://dx.doi.org/10.1186/s13244-021-01026-1 |
Ejemplares similares
-
Comparison of Positron Emission Tomography Using 2-[(18)F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[(18)F]-fluorothymidine in Lung Cancer Imaging
por: Wang, Fu-Li, et al.
Publicado: (2016) -
The Positron Emission Tomography Tracer 3’-Deoxy-3’-[(18)F]Fluorothymidine ([(18)F]FLT) Is Not Suitable to Detect Tissue Proliferation Induced by Systemic Yersinia enterocolitica Infection in Mice
por: Wiehr, Stefan, et al.
Publicado: (2016) -
Comparison of (18)F-fluorothymidine Positron Emission Tomography/Computed Tomography and (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Breast Cancer
por: Mori, Mio, et al.
Publicado: (2022) -
Role of 3'-Deoxy-3'-[(18)F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase
por: Szyszko, Teresa A., et al.
Publicado: (2022) -
3’-Deoxy-3’-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study
por: Lewis, Shirley, et al.
Publicado: (2022)